DNA ploidy and p53 protein expression in superficial transitional cell carcinoma of the bladder

Cytopathology

Volumn 11, Issue 2, 2000, Pages 96-103

  Ioakim Liossi, A ^a,e   Pantazopoulos, D ^b   Karakitsos, P ^c   Athanassiadou, P ^a   Aroni, K ^a   Chourdakis, N ^a   Giachnaki, A ^a   Athanassiades, P ^d  

^a Cytopathology Unit   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c 'S Olga' Hospital   (Greece)

^d ALEXANDRA HOSPITAL   (Greece)

^e NONE   (Greece)

Author keywords

DNA ploidy; Immunocytochemistry; P53 protein; Superficial transitional cell carcinoma of the bladder

Indexed keywords

AVIDIN; DNA; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER RECURRENCE; DNA CONTENT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PLOIDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA;

CARCINOMA, TRANSITIONAL CELL; DNA, NEOPLASM; FEMALE; HUMANS; MALE; PLOIDIES; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0034002216     PISSN: 09565507     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2303.2000.00225.x     Document Type: Article

References (39)

1. 1 Soloway M. Managing superficial bladder cancer: an overview. Urology 1992; 40 ( Suppl. 6): 5-10.
2. 2 Holmang S, Hedelin H, Anderstrom C, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stages TA and TI transitional cell cancer of the bladder followed up for at least 20 years. J Urol 1995; 153: 1823-7.
3. 3 Gustafson H, Tribukait B, Esposti PL. DNA profile and tumor progression in patients with superficial bladder tumours. Urol Res 1982; 10: 13-18.
4. 4 de Vere White RW, Deitch AD, West B et al. The predictive value of flow cytometric information in the clinical management of stage 0 (Ta) bladder cancer. J Urol 1988; 139: 279-82.
5. 5 Tachibana M, Deguchi N, Baba S et al. Multivariate analysis of flow cytometric deoxyribonucleic acid parameters and histological features for prognosis of bladder cancer patients. J Urol 1991; 146: 1530-4.
6. 6 Norming U, Tribukait B, Nyman CR et al. Prognostic significance of mucosal aneuploidy in stage Ta/II grade 3 carcinoma of the bladder. J Urol 1992; 148: 1420-7.
7. 7 Jacobsen AB, Pettersen EO, Amellem O et al. The prognostic significance of deoxyribonucleic acid flow cytometry in muscle invasive bladder carcinoma treated with preoperative irradiation and cystectomy. J Urol 1992; 147: 34-37.
8. 8 Wright C, Thomas D, Mellon K, Neal DE, Wilson Horne CH. Expression of retinoblastoma gene product and p53 protein in bladder carcinoma: correlation with Ki-67 index. Br J Urol 1995; 75: 173-9.
9. 9 Auer GU, Falkmer UG, Zetterberg AD. Image cytometric nuclear DNA analysis in clinical tumour material. In: Baak JPA, ed. Manual of Quantitative Pathology in Cancer Diagnosis and Prognosis. Berlin: Springer-Verlag, 1991: 218-20.
10. 10 Dowell SP. p53 immunocytochemical staining in diagnostic cytopathology: the relevance of the proportion of positive cells. Cytopathology 1995; 6: 361-2.
11. 11 Raghavan D, Shipley W, Garnick M et al. Biology and management of bladder cancer. N Engl J Med 1990; 322: 1129-38.
12. 12 Bozzetti C, Nizzoli R, Naldi N et al. Fine-needle aspiration technique for the concurrent immunocytochemical evaluation of multiple biologic parameters in primary breast carcinoma. Breast Cancer Res Treat 1994; 32: 221-8.
13. 13 Pelozi G, Bresaola E, Rodella S et al. Expression of proliferating cell nuclear antigen, Ki-67 antigen, estrogen receptor protein and tumor suppressor p53 gene in cytological samples of breast cancer. An immunocytochemical study with clinical, pathological and histological correlations. Diagn Cytopathol 1994; 11: 131-40.
14. 14 Stephenson TJ, Royds JA, Silcocks PB, Brammer HJ, Shorthouse AJ, Underwood JCE. Diagnostic associations of p53 immunostaining in fine needle aspiration cytology of the breast. Cytopathology 1994; 5: 146-53.
15. 15 Pycha A, Mian Ch, Haitel A, Hofbauer J, Wiener H, Marberger M. Fluorescence in situ hybridization identifies more aggressive types of primarily noninvasive (stage pTa) bladder cancer. J Urol 1997; 157: 2116-9.
16. 16 Colecchia M, Frigo B, Zucchi Leopardi O. p53 protein expression in fine-needle aspirates of breast cancer: an immunocytochemical assay for identifying high-grade ductal carcinomas. Diagn Cytopathol 1995; 13: 128-33.
17. 17 Ioakim-Liossi A, Karakitsos P, Markopoulos Ch et al. DNA content and p53 protein expression in ductal breast cancer. Cytopathology 1997; 8: 322-7.
18. 18 Ioakim-Liossi A, Karakitsos P, Aroni K et al. p53 protein expression and DNA ploidy in common epithelial tumors of the ovary. Acta Cytologica 1997; 41: 1714-8.
19. 19 Kihana T, Tsuda H, Teshima O, Okada S, Metsura S, Hirohashi S. High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy. Jpn J Cancer Res 1992; 83: 978-84.
20. 20 Cordon-Cardo C, Zhang Z-F, Dalbagni G et al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 1997; 57: 1217-21.
21. 21 Nakopoulou L, Constantinides C, Papandropoulos J et al. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy. Urology 1995; 46: 334-40.
22. 22 Serth J, Cuezyk MA, Bokemeyer C et al. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 1995; 71: 201-5.
23. 23 Tetu B, Fradet Y, Allard P, Veilleux C, Roberge N, Bernard P. Prevalence and clinical significance of HER-2/neu, p53 and Rb expression in primary superficial bladder cancer. J Urol 1996; 155: 1784-8.
24. 24 Burkhard FC, Markwalder R, Thalmann GN, Studer UE. Immunohistochemical determination of p53 overexpression. An easy and readily available method to identify progression in superficial bladder cancer. Urol Res 1997; 25 (Suppl. 1): S31-35.
25. 25 Vojtesek B, Bartek J, Midglu CA, Lane DP. An immunohistochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 1992; 151: 237-44.
26. 26 Esrig D, Spruck CH III, Nichols PW et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade and stage in bladder cancer. Am J Pathol 1993; 143: 1389-97.
27. 27 Lipponen PK. Over-expression of p53 nuclear oncoprotein in transitional cell bladder cancer and its prognostic value. Int J Cancer 1993; 53: 365-70.
28. 28 Sarkis AS, Dalbagni G, Cordon-Cardo C et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker of disease progression. J Natl Cancer Inst 1993; 85: 53-59.
29. 29 Shiina H, Igawa M, Nagami H et al. Immunohistochemical analysis of proliferating cell nuclear antigen. p53 protein and nm23 protein and nuclear DNA content in transitional cell carcinoma of the bladder. Cancer 1996; 78: 1762-74.
30. 30 Liukkonen TJ, Lipponen PK, Helle M, Jauhiainen KC. Immunoreactivity of bcl-2, p53 and EGFr is associated with tumor stage, grade and cell proliferation in superficial bladder cancer. Finnblader III group. Urol Res 1997; 25: 1-7.
31. 31 Wheeless LL, Badalament RA, de Vere White RW et al. Consensus review of the clinical utility of DNA cytometry in bladder cancer. Cytometry 1993; 14: 478-81.
32. 32 Schapers RF, Ploem-Saaijer JJ, Pauwels RP et al. Image cytometric analysis in transitional cell carcinoma of the bladder. Cancer 1993; 72: 182-9.
33. 33 Boking A, Striepeeke E, Auer H, Fusesi L. Static DNA cytometry. In: Wied GL, Bartels PH, Rosenthal DL, Schenk U, eds. Compendium on the Computerized Cytology and Histology Laboratory. Chicago: T.O.C., 1994: 107-28.
34. 34 Al-Abadi H, Borgmann V, Nagel R. Transitional cell carcinoma of the urinary bladder: DNA-cytometric analysis in relation to the grade, stage and clinical course. A follow-up study of 9 years. In: Giulieni L, Luppo P, eds. Urology 1992 Bologna: Monduzzi Editore. 1992: 429-31.
35. 35 Sun X. Prognostic significance of DNA content in transitional cell carcinoma of the urinary bladder. Clin J Oncol (English Abstract) 1992; 14: 24-26.
36. 36 Pantazopoulos D, Ioakim-Liossi A, Karakitsos P et al. DNA content and proliferation activity in superficial transitional cell carcinoma of the bladder. Anticancer Res 1997; 17: 781-6.
37. 37 Hofstaedter F, Jakse G, Lederer B, Mikuz G, Delgado R. Biological behaviour and DNA cytophotometry of urothelial bladder carcinoma. Br J Urol 1984; 56: 289-95.
38. 38 van Velthonen R, Petein M, Oosterlinck W et al. Image cytometry determination of ploidy level, proliferative activity, and nuclear size in a series of 314 transitional bladder cell carcinomas. Hum Pathol 1995; 26: 3-11.
39. 39 Raitanen MP, Tammela TL, Kallioinen M, Isola J. p53 accumulation, deoxyribonucleic acid ploidy and progression of bladder cancer. J Urol 1997; 157: 1250-3.